Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways

Figure 8

Dual effect of Vericiguat on RANKL-induced osteoclastogenesis and molecular mechanism. There may be a potential balance between the IκB-α/NF-κB signaling pathway and sGC/cGMP/VASP in BMMs. Vericiguat at low doses (0-2 μmol/l) enhanced RANKL-induced osteoclastogenesis dominantly through upregulation of the VASP/IκB-α/NF-κB signaling pathway, whereas Vericiguat at high doses (4 or 8 μmol/L) suppressed RANKL-induced osteoclastogenesis through directly inhibiting the IκB-α/NF-κB signaling pathway signaling cascade, which could disturb VASP-mediated activation of the IκB-α/NF-κB signaling pathway.